Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Asian Stocks Slide as Central Bank Decisions and Key Data Keep Investors Cautious 
U.S. Stock Futures Mixed as Tech and AI Stocks Face Pressure Ahead of CPI Data 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
New Zealand Budget Outlook Shows Prolonged Deficits Despite Economic Recovery Hopes 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Celltrion biopharmaceutical company is combining three of its business units as its founder, Seo Jung Jin, returns to the management. He said earlier this week that they would also pursue mergers and acquisition (M&A) opportunities while working on consolidating the three divisions to help fortify the operations of the company.
Moreover, the Celltrion Group is looking to acquire the biopharma solutions business of Baxter International Inc. As per Pulse News, the company is planning to merge its three units - Celltrion Inc., Celltrion Pharm Inc., and Celltrion Healthcare Co. The target date for the completion of this plan is by the end of this year, and this was shared by Seo Jung Jin himself at the recent shareholders’ meeting.
Seo first established Celltrion Inc. in 2002, and he has been leading the company until he stepped down in March 2021. He has assumed an honorary position since then, and now he is back in the company after a 2-year hiatus and will hold a managerial role.
The Celltrion founder was appointed as co-chairman of the board of the three businesses that will be combined to form one unit. He will be in this position for two years.
“We may make our move on the potential takeover of Baxter’s biopharma unit at the end of the year as we hold sufficient cash for now,” Seo stated during the conference regarding the merger of the three Celltrion firms. “We will file a report to the financial regulator in July.”
“The merger will be realized at the end of the year at the earliest, though we have to see how the financial situation goes,” he added via a separate statement after the meeting on Tuesday.
Korea Joongang Daily reported that Seo already revealed the plans for the integration of Celltrion’s three listed companies in early 2020. However, he left the company the following year. Thus, upon his return, the merger was one of the things that he would like to fulfill.
